Royalty Pharma Plc (RPRX)
Healthcare
Biotechnology
58.40 $
-1.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Royalty Pharma Plc (RPRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 93.3% of the shares are freely tradable; institutional investors hold 88.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
88.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
6.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
93.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
2.6%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
443Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Morgan Stanley - Brokerage Accounts | 9.83 | 43,571,633 | -21.2 | 03/31/2026 |
| Capital Research & Mgmt Co - Division 3 | 7.90 | 35,005,736 | +12.5 | 03/31/2026 |
| BlackRock Inc | 5.84 | 25,907,745 | -1.1 | 03/31/2026 |
| FMR Inc | 5.67 | 25,152,242 | -4.3 | 03/31/2026 |
| Baillie Gifford & Co Limited. | 3.64 | 16,155,677 | -5.0 | 03/31/2026 |
| Swedbank AB | 2.61 | 11,586,693 | -3.0 | 03/31/2026 |
| State Street Corp | 2.48 | 10,989,851 | +3.2 | 03/31/2026 |
| Vanguard Group Inc | 2.24 | 9,934,612 | -9.2 | 12/31/2025 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| American Funds New Perspective A | 4.43 | 19,645,749 | +94.7 | 03/31/2026 |
| Capital Group New Perspective Comp | 4.43 | 19,645,749 | +94.7 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.